Sony CGX10 Fully Enclosed Flow Cytometric Cell Sorter

Overview

The Sony CGX10 Fully Enclosed Flow Cytometric Cell Sorter is an engineered solution for high-fidelity, multi-parameter cell isolation in regulated biomanufacturing environments. Unlike conventional magnetic-activated cell sorting (MACS) systems—which rely on single-antigen targeting and yield heterogeneous populations—the CGX10 employs hydrodynamic focusing and real-time optical interrogation to resolve complex immune phenotypes with single-cell resolution. Its core architecture integrates four solid-state lasers (405 nm, 488 nm, 561 nm, 638 nm) with eight fluorescence detection channels plus forward and side scatter (FSC/SSC), enabling simultaneous assessment of surface marker density, intracellular signaling states, and morphological features. Designed specifically for clinical-scale cell therapy workflows, the system operates entirely within a sterile, closed fluidic path—eliminating open-tube handling, aerosol generation, and operator-dependent contamination risks. This design directly addresses critical process requirements defined in ICH Q5A(R2), USP <1043>, and ISO 20387 for human cell-based products, ensuring consistent lot-to-lot identity, purity, and viability.

Key Features

• Fully enclosed, single-use microfluidic cartridge system—pre-sterilized, gamma-irradiated, and manufactured under ISO 13485-certified conditions; each batch supplied with full traceability documentation supporting GMP readiness.
• High-speed, high-purity sorting at ≥33,000 events/sec with post-sort viability >95% (measured via Annexin V/7-AAD and metabolic assays), validated across primary T cells, NK cells, HSCs, MSCs, and iPSC-derived lineages.
• Automated setup protocol eliminates reliance on calibration beads; instrument self-aligns optics, verifies laser stability, and establishes baseline PMT voltages prior to acquisition—reducing startup time to <5 minutes.
• Intuitive software interface with guided SOP modules compliant with ALCOA+ data integrity principles; includes preconfigured templates for CAR-T enrichment, Treg isolation, and hematopoietic progenitor purification.
• Real-time compensation engine supports both on-the-fly spectral unmixing and offline reanalysis using saved spillover matrices—ensuring reproducibility across operators and shifts.

Sample Compatibility & Compliance

The CGX10 accommodates anticoagulated whole blood, PBMC suspensions, bone marrow aspirates, and enzymatically dissociated tissue digests (e.g., tumor-infiltrating lymphocytes). All sample input volumes are compatible with standard 12 × 75 mm polystyrene tubes or integrated sample reservoirs. The system meets essential regulatory benchmarks for cell therapy manufacturing: it supports 21 CFR Part 11-compliant electronic records through role-based access control, audit trail logging (including parameter changes, gate adjustments, and sort logic modifications), and electronic signatures. Full compliance documentation—including Design Qualification (DQ), Installation Qualification (IQ), and Operational Qualification (OQ) protocols—is available upon request. All consumables carry CE-IVD marking and are registered with the Japanese PMDA as Class III in vitro diagnostic devices.

Software & Data Management

The proprietary CGX10 Control Software v3.x provides end-to-end workflow management—from acquisition and gating to sorting decision logic and post-run QC reporting. Raw FCS 3.1 files are generated with embedded metadata (instrument settings, user ID, timestamp, lot numbers of reagents/cartridges). Integrated analysis tools include t-SNE and UMAP dimensionality reduction, automated population identification via FlowSOM clustering, and batch correction algorithms for longitudinal studies. Audit trails record all user actions with immutable timestamps and IP address attribution. Data export supports CSV, PDF, and structured JSON formats compatible with LIMS integration and statistical platforms such as R/Bioconductor and Python’s Scanpy ecosystem.

Applications

• CAR-T and CAR-NK manufacturing: Isolation of CD4+/CD8+ subsets with defined memory phenotypes (e.g., T_SCM, T_CM) to enhance persistence and anti-tumor efficacy.
• Treg expansion protocols: Precise separation of FOXP3⁺CD25^hiCD127^lo cells from activated effector T cells without exogenous cytokine stimulation.
• HSC/MSC banking: Enrichment of CD34⁺CD90⁺CD45RA⁻ hematopoietic stem cells or CD73⁺CD90⁺CD105⁺ mesenchymal stromal cells with minimal culture-induced differentiation.
• iPSC-derived therapeutic products: Removal of residual undifferentiated pluripotent cells (SSEA-4⁺/TRA-1-60⁺) to mitigate teratoma risk in final drug substance.
• TCR-engineered T cell development: Multiparametric sorting based on transgenic TCR expression level, activation status (CD69, HLA-DR), and exhaustion markers (PD-1, TIM-3).

FAQ

Is the CGX10 compliant with FDA 21 CFR Part 11 requirements?

Yes—the system implements full electronic signature capability, secure user authentication, and immutable audit trails covering all analytical and sorting operations.
Can the CGX10 be integrated into existing cleanroom workflows?

Yes—its compact footprint (65 cm × 70 cm × 55 cm), low heat dissipation (<150 W), and compatibility with Class A/B isolators enable seamless installation in ISO 5–7 environments.
What validation support is provided for GMP implementation?

Sony supplies IQ/OQ protocols, PQ templates aligned with PDA Technical Report No. 81, and vendor-qualified third-party verification services for facility-specific performance qualification.
Does the system support custom antibody panel configuration?

Yes—users may define arbitrary combinations of fluorochromes and configure detector voltage ranges, threshold triggers, and sort logic gates without firmware modification.
How is instrument performance monitored over time?

Daily QC is performed using NIST-traceable reference particles; long-term stability is tracked via built-in CV monitoring across all detectors with automated alerts for drift exceeding ±1.5%.